AIMS: To evaluate the effect of metformin on glucose metabolism, insulin sensitivity and rate of conversion diabetes in people with impaired glucose tolerance (IGT). METHODS:Seventy subjects with IGT were randomized under double-blind conditions to receive either placebo (n = 37) or metformin (n = 33) at a dosage of 250 mg three times daily for a duration of 12 months. Glycaemic control, plasma insulin and other biochemical indexes were assessed before and after 3, 6 and 12 months. RESULT: At 12 months the conversion rate to diabetes was 16.2% in the placebo group compared to 3.0% for the metformin group (P = 0.011). Of subjects treated with metformin for 12 months, 84.9% became normoglycaemic compared to 51.4% of those receiving the placebo. Significant improvements in fasting glucose, glucose tolerance and insulin sensitivity were found at 12 months and at intermediate clinic assessments. CONCLUSIONS:Metformin can improve glucose metabolism in IGT patients and may be a treatment option in their management of IGT subjects.
RCT Entities:
AIMS: To evaluate the effect of metformin on glucose metabolism, insulin sensitivity and rate of conversion diabetes in people with impaired glucose tolerance (IGT). METHODS: Seventy subjects with IGT were randomized under double-blind conditions to receive either placebo (n = 37) or metformin (n = 33) at a dosage of 250 mg three times daily for a duration of 12 months. Glycaemic control, plasma insulin and other biochemical indexes were assessed before and after 3, 6 and 12 months. RESULT: At 12 months the conversion rate to diabetes was 16.2% in the placebo group compared to 3.0% for the metformin group (P = 0.011). Of subjects treated with metformin for 12 months, 84.9% became normoglycaemic compared to 51.4% of those receiving the placebo. Significant improvements in fasting glucose, glucose tolerance and insulin sensitivity were found at 12 months and at intermediate clinic assessments. CONCLUSIONS:Metformin can improve glucose metabolism in IGT patients and may be a treatment option in their management of IGT subjects.
Authors: Anna Glechner; Jürgen Harreiter; Gerald Gartlehner; Sonja Rohleder; Alexander Kautzky; Jaakko Tuomilehto; Megan Van Noord; Angela Kaminski-Hartenthaler; Alexandra Kautzky-Willer Journal: Diabetologia Date: 2014-12-03 Impact factor: 10.122
Authors: J Sonya Haw; Karla I Galaviz; Audrey N Straus; Alysse J Kowalski; Matthew J Magee; Mary Beth Weber; Jingkai Wei; K M Venkat Narayan; Mohammed K Ali Journal: JAMA Intern Med Date: 2017-12-01 Impact factor: 21.873